AI ScreeningAI ChatPricing
  1. JP-listed companies
  3. Financials
  4. Net income margin (%)

【JP:4892】

Market cap
¥5.1B
P/E ratio
-5.6x
Cyfuse develops 3D tissues and organs made entirely from human cells for regenerative medicine, drug discovery, and medical device applications.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income margin (%) YoY (%)
Dec 31, 2025-330.3-79.38%
Dec 31, 2024-1,602+66.16%
Dec 31, 2023-964.1+661.77%
Dec 31, 2022-126.6-727.27%
Dec 31, 202120.2-108.42%
Dec 31, 2020-239.7-21.42%
Dec 31, 2019-305-79.34%
Dec 31, 2018-1,476.2+192.66%
Dec 31, 2017-504.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)